The risk of ovarian cancer associated with infertility and infertility treatments.

Croughan-Minihane, Mary S.; Camarano, L.; Feigenbaum, Seth L.; Nelson, H.; Adamson, G. David; Cadieux, Magalie

doi:10.1016/s0015-0282(01)02216-6

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another United States published abstract, it was also found no effect of ovulation‐inducing drugs on ovarian cancer risk by Croughan‐Minihane et al 19 After 5.6 years of follow‐up of 51,371 patients seen for conception difficulties or ovum donation in 15 California clinics between 1965 and 1998, 50 ovarian cancers were diagnosed. Several recent cohort studies have failed to provide confirmatory evidence for a large increase in ovarian cancer risk associated with use of FD.…”

Section: Ovarian Cancermentioning

confidence: 96%

“…Three lines of evidence raise concern regarding potential effects of ovulationinducing drugs on cancer risk. First the most commonly used medications, 18 3,837 1974-1985 12.3 Australia (Venn et al) 22 10,358 1978-1992 6.5 Israel (Modan et al) 37 2,496 1964-1974 21.4 Israel (Potashnik et al) 26 1,197 1960-1984 17.9 USA (Croughan-Minihane et al) 19 51,371 1965-1998 5.6 Netherlands (Klip et al) 23 25,152 1980-1995 5.6 UK (Doyle et al) 24 5,556 1975-1989 7.9 USA (Brinton et al) 20 12,193 1965-1988 18.8 Israel (Dor et al) 27 5,026 1981-1992 3.6 Israel (Lerner-Geva et al) 48 1,082 1984-1992 6.5 clomiphene citrate and gonadotropins, are effective for stimulating ovulation, a factor implicated in the etiology of both breast and ovarian cancers. Second, these drugs raise both E 2 and P levels, hormones that are recognized as affecting the development and growth of breast and gynecology cancers as well as some other cancers.…”

Section: Cancer Incidence Following Treatment For Infertilitymentioning

confidence: 99%

See 1 more Smart Citation

Fertility Drugs and Gynecologic Cancer

Kanakas

Mantzavinos

2006

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Fertility drugs (FD) are spreading worldwide fast and therefore many studies have reviewed the possible association between the use of these drugs and cancer. Since the drugs used for ovulation induction during in vitro fertilization (IVF) like hCG, hMG, rFSH increase the levels of gonadal hormones, concerns have grown regarding the risk of developing cancer in breast, ovary, endometrium, and other target organs. In this review, we discuss a number of different studies published in recent years that show no association between the use of these drugs and most cancers.

show abstract

Section: Ovarian Cancermentioning

confidence: 96%

Section: Cancer Incidence Following Treatment For Infertilitymentioning

confidence: 99%

Fertility Drugs and Gynecologic Cancer

Kanakas

Mantzavinos

2006

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…These two studies prompted several other investigations, including cohort studies in Australia, 18,48 Israel, 14,16,49,50 the United States, 28,51 the Netherlands, 29 the United Kingdom, 52,53 Denmark, 54 and Sweden. [55][56][57] Most of these studies failed to provide confirmation of a link between fertility drug use and ovarian cancers.…”

Section: Cohort Studiesmentioning

confidence: 99%

“…52 Although these previously discussed studies focused on women exposed to ovulation-inducing agents at earlier times, several other studies have concentrated on exposures received during IVF. One study that derived data from 15 California clinics, published to date only in abstract form, 51 in which 50 ovarian cancers developed among 51,371 women, found no evidence for an association of fertility drugs with ovarian cancer risk, even when dose, formulation, and number of treatment cycles were considered.…”

Section: Cohort Studiesmentioning

confidence: 99%

Fertility Drugs and the Risk of Breast and Gynecologic Cancers

2012

View full text Add to dashboard Cite

The evaluation of cancer risk among patients treated for infertility is complex, given the need to consider indications for use, treatment details, and the effects of other factors (including parity status) that independently affect cancer risk. Many studies have had methodologic limitations. Recent studies that have overcome some of these limitations have not confirmed a link between drug use and invasive ovarian cancers, although there is still a lingering question as to whether borderline tumors might be increased. It is unclear whether this merely reflects increased surveillance. Investigations regarding breast cancer risk have produced inconsistent results. In contrast, an increasing number of studies suggest that fertility drugs may have a special predisposition for the development of uterine cancers, of interest given that these tumors are recognized as particularly hormonally responsive. Additional studies are needed to clarify the effects on cancer risk of fertility drugs, especially those used in conjunction with in vitro fertilization. Because many women who have received such treatments are still relatively young, further monitoring should be pursued in large well-designed studies that enable assessment of effects within a variety of subgroups defined by both patient and disease characteristics.

show abstract

“…Em outro estudo de coorte retrospectiva com 3.837 mulheres avaliadas para infertilidade na cidade de Seattle entre os anos de 1974 e 1985, o uso de citrato de clomifeno esteve associado com um risco ajustado de 2,3 vezes maior para câncer de ovário (48). Contudo, estudos mais recentes e metodologicamente mais adequados não reproduziram estes achados de aumento de risco relacionado à utilização de citrato de clomifeno ou gonadotrofinas (49,50). Assim, as evidências atuais não permitem afirmar de forma conclusiva que haja associação entre uso de drogas para indução de ovulação e câncer ovariano.…”

Section: Câncer De Endométriounclassified

Neoplasias associadas à síndrome dos ovários policísticos

Spritzer

Morsch

Wiltgen

2005

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women on reproductive age. PCOS is characterized by the presence of anovulation, infertility and hyperandrogenism and is associated with obesity and insulin resistance. A major risk for neoplasms of the reproductive tract, like endometrial, breast and ovary cancer seems to be related to PCOS. While several studies have shown an increased risk for endometrial hyperplasia and cancer in PCOS patients, the variability of the selection criteria for PCOS has been recognized as a potential bias for these data. PCOS women also present clinical characteristics that are related to risk factors for breast cancer and some epidemiological evidences have been described on this issue. However, until now, a clear association between the presence of PCOS and breast carcinoma has yet not been found. Finally, high local steroid and growth factor concentrations are considered risk factors for ovary carcinoma, and are frequently observed in PCOS women. In turn, few studies have addressed the possibility of a link between PCOS and ovarian cancer and the results are conflicting but suggest that this association is unlikely.

show abstract

The risk of ovarian cancer associated with infertility and infertility treatments.

Cited by 8 publications

References 0 publications

Fertility Drugs and Gynecologic Cancer

Fertility Drugs and Gynecologic Cancer

Fertility Drugs and the Risk of Breast and Gynecologic Cancers

Neoplasias associadas à síndrome dos ovários policísticos

Contact Info

Product

Resources

About